Diabetic Retinopathy Market Report 2026

The diabetic retinopathy market size has grown strongly in recent years. It will grow from $9.26 billion in 2025 to $9.97 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing diabetes prevalence, late diagnosis of retinal damage, limited screening access, rising vision impairment cases, dependence on hospital-based eye care.

The diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $13.54 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growth of ai-assisted screening tools, expansion of ophthalmology clinics, increasing anti-vegf therapy adoption, focus on preventive eye care, rising aging diabetic population. Major trends in the forecast period include rising adoption of retinal screening programs, increased use of anti-vegf therapies, expansion of early detection and monitoring, growing integration of AI-based retinal imaging, rising focus on vision preservation.

The increasing prevalence of diabetes is expected to drive the growth of the diabetic retinopathy market in the coming years. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels. The rise in diabetes prevalence is largely driven by factors such as overweight, obesity, genetic predisposition, and physical inactivity. Persistently high blood sugar levels can damage the retina, the part of the eye responsible for sensing light and transmitting visual signals to the brain through the optic nerve. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes it rose by 21%. Additionally, the share of people achieving target HbA1c levels reached 37.9%, the highest level recorded by the National Diabetes Audit. Therefore, the growing prevalence of diabetes is contributing to the expansion of the diabetic retinopathy market.

Major companies operating in the diabetic retinopathy market are increasingly engaging in partnerships to enhance their market presence and profitability. Partnerships in diabetic retinopathy involve collaborative efforts among healthcare providers, researchers, pharmaceutical companies, and technology firms to address challenges in screening, diagnosis, and management of the condition. For instance, in October 2023, AEYE Health, a US-based provider of artificial intelligence-driven retinal diagnostics, partnered with Topcon Screen, a Japan-based diabetic screening platform. This collaboration aims to enable point-of-care diabetic retinopathy screening using AI, delivering rapid and accurate results that allow primary care clinicians to conduct screenings directly within their clinics. This approach is intended to reduce patient non-compliance and close care gaps by providing immediate and reliable assessments at the point of care.

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed amount. Through this acquisition, Regeneron gains access to Oxular’s proprietary sustained-release Oxuspheres technology and its Oxulumis suprachoroidal microcatheter delivery system. This strengthens Regeneron’s retinal drug delivery capabilities and expands its therapeutic reach in ophthalmology. Oxular Limited is a UK-based biotechnology company specializing in long-acting drug formulations and targeted delivery platforms for retinal diseases, including posterior-segment disorders.

Major companies operating in the diabetic retinopathy market are Pfizer Inc., F‑Hoffmann‑La Roche Ltd., Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc., Genentech Inc., Santen Pharmaceutical Co Ltd., Carl Zeiss Meditec AG, Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co Ltd., IRIDEX Corporation, Alimera Science Inc., Oxurion NV, EyePoint Pharmaceuticals, Opthea Limited, KalVista Pharmaceuticals Inc., Regenxbio Inc., Kodiak Sciences Inc., Oculis, Verseon International Corporation, Clearside Biomedical Inc.

North America was the largest region in the diabetic retinopathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic retinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic retinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetic retinopathy market by increasing costs of imported retinal imaging systems, anti-VEGF drugs, and ophthalmic surgical equipment. Hospitals and eye clinics in North America and Europe are most affected due to reliance on imported technologies, while Asia-Pacific faces higher diagnostic equipment costs. These tariffs increase treatment expenses. However, they also encourage local manufacturing of imaging devices and regional pharmaceutical production.

The diabetic retinopathy market research report is one of a series of new reports that provides diabetic retinopathy market statistics, including diabetic retinopathy industry global market size, regional shares, competitors with a diabetic retinopathy market share, detailed diabetic retinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic retinopathy industry. This diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic retinopathy is a diabetes-related complication that affects the retina, the light-sensitive tissue at the back of the eye, and occurs due to damage to blood vessels caused by prolonged high blood sugar levels. If not properly managed, this condition can result in vision impairment or blindness, highlighting the importance of regular eye examinations for early diagnosis and timely treatment.

The main types of diabetic retinopathy are proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. Proliferative diabetic retinopathy represents the advanced stage of the disease, characterized by the growth of abnormal new blood vessels on the surface of the retina. Treatment options include anti-VEGF drugs, intraocular steroid injections, laser photocoagulation, and vitreoretinal surgery, which are performed in hospitals, ambulatory surgical centers, and other healthcare settings.

The diabetic retinopathy market includes revenues earned by entities by providing ophthalmologic examination, eye management and retinal imaging and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.